A PHASE Ib/ll, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER)
|F. Hoffmann - La Roche Ltd
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment.
This study is closed
Gulam Manji, MD, PhD
|Are you 18 years or older?
|Do you have pancreatic ductal adenocarcinoma that continues to grow despite standard therapy?
|Are you able to walk, care for yourself, and do light physical activities like light housework or office work?